GRPR and neoplasm: The use of tumour-specific tracers, targeting, for example, ER (e.g. [18F]FES), HER2 (e.g. [68Ga]ABY-025), PARP (e.g. [18F]SuPAR), FAP (e.g. [68Ga]FAPI) or GRPR (e.g. [68Ga]RM2) [27–31] are likely to further improve the diagnostic accuracy of FAR.